Is LABD a Buy? What to Consider in 2026

Direxion Daily S&P Biotech Bear 3X Shares (LABD) is a geared inverse exchange-traded fund that seeks daily investment results, before fees and expenses, equal to 300% of the inverse (-3x) of the daily performance of the S&P Biotechnology Select Industry Index. The fund uses swaps, futures, and short positions rather than holding a portfolio of stocks, so its disclosed holdings are derivative and cash instruments rather than individual companies. The S&P Biotechnology Select Industry Index is an equal-weighted basket of US biotechnology firms, a sector already known for sharp, news-driven swings around clinical trials, FDA decisions, and earnings. Applying -3x leverage to that base magnifies both gains and losses. Critically, LABD targets its -3x exposure on a single-day basis and rebalances daily. Over any holding period longer than one day, the compounding of daily returns means LABD's performance can diverge substantially from -3x the index's cumulative return, and in choppy or sideways markets this compounding works against holders, eroding value even if biotech is roughly flat. LABD carries a gross expense ratio around 1.07% (net near 0.95%), well above plain index funds, which adds a further long-term drag. It is designed for sophisticated traders seeking to profit from or hedge against short-term declines in biotech, with positions actively monitored and typically held for days, not months. Its bull counterpart is LABU (Direxion Daily S&P Biotech Bull 3X Shares), which seeks +3x the same index.

Largest holdings (approximate as of early 2026; verify on Direxion's fund page):

LABD is Direxion's -3x inverse leveraged biotech ETF: it seeks 300% of the opposite of the daily move in the S&P Biotechnology Select Industry index, so it gains when biotech falls. It is a short-term hedging and trading instrument only. Daily resetting plus already-volatile biotech means it suffers compounding decay and tends to lose value if held longer than a day or two, regardless of the index's direction.

In its favour: it gives you -3x daily S&P Biotech Select Industry exposure in one ticker at a 1.07% (gross; about 0.95% net of acquired fund fees) expense ratio, which is simple to hold and cheap to own.

• Cost vs alternatives: 1.07% (gross; about 0.95% net of acquired fund fees) is the fee; compare it to funds tracking a similar index.
• Concentration: check how much of LABD sits in its largest holdings ().
• Overlap: if you already own a broad-market fund, you may already hold much of this.
• Tracking scope: LABD only gives you -3x daily S&P Biotech Select Industry; it will not capture what sits outside that index.

The useful question is rarely “will LABD go up?” It is “does this exposure fit my plan, at a cost I am happy with, without doubling up on what I already own?” Walnut connects your real brokerage so you can see exactly how LABD would overlap with your current holdings, analyze it by chatting through Claude or ChatGPT, and place any trade yourself. You stay in control.

The bottom line: LABD is a low-cost core building block for -3x daily S&P Biotech Select Industry exposure, not a tactical bet on a single name. If you want -3x daily S&P Biotech Select Industry exposure and the 1.07% (gross; about 0.95% net of acquired fund fees) fee is competitive for you, it does its job well. If you already own that exposure through another fund, adding it mostly doubles a fee without adding diversification. Decide from your goal and your existing holdings, not from where the market sat last week. Walnut is not an investment adviser.